<p>週二，彭博社報道，皇家銀行的股票研究員重申了對氙製藥（Xenon Pharmaceuticals，NASDAQ：XENE）的&#34;表現優異&#34;評級。他們目前將這家生物製藥公司的股票定價目標定為 55.00 美元。皇家銀行的股價目標顯示，相較於當前股價，潛在上漲空間為 33.24%。</p>
<p>獲取 <strong>氙製藥</strong> 的警報：</p>
<ul>
<li>百時美施貴寶的大舉購買：在兩筆生物科技交易中斥資 181 億美元</li>
</ul>
<p>其他一些分析師最近也發佈了關於 XENE 的報告。卡恩特菲茨傑拉德（Cantor Fitzgerald）重申了&#34;超重&#34;評級，並在 8 月 9 日星期五的研究報告中給出了 65.00 美元的股價目標。Wedbush 在 8 月 9 日星期五的研究報告中將氙製藥的股價目標從 50.00 美元降至 49.00 美元，並給予&#34;表現優異&#34;評級。Needham &amp; Company LLC 在 8 月 12 日星期一的研究報告中將氙製藥的目標股價從 62.00 美元降至 60.00 美元，並給予&#34;買入&#34;評級。最後，花旗集團在 5 月 10 日星期五的報告中將氙製藥的股價目標從 62.00 美元降至 60.00 美元，並給予&#34;買入&#34;評級。一位投資分析師對該股票給予賣出評級，而九位分析師則給予該公司股票買入評級。根據 MarketBeat.com 的數據，氙製藥目前的共識評級為&#34;中度買入&#34;，平均目標股價為 58.78 美元。</p>
<p><strong>閲讀我們關於 XENE 的最新股票分析</strong></p>
<h2>氙製藥股價上漲 2.3%</h2>
<p>週二交易日，氙製藥股價上漲 0.94 美元，達到 41.28 美元。該公司的交易量為 14,893 股，相比平均交易量 395,175 股。該公司的市值為 31.3 億美元，市盈率為-15.10，貝塔係數為 1.25。該公司的 50 天簡單移動平均線為 40.29 美元，200 天簡單移動平均線為 41.46 美元。氙製藥的 52 周最低價為 27.99 美元，52 周最高價為 50.99 美元。</p>
<p>氙製藥（Xenon Pharmaceuticals，NASDAQ：XENE）於 8 月 8 日星期四公佈了季度財報。這家生物製藥公司在該季度報告中每股虧損 0.75 美元，低於每股虧損 0.70 美元的共識預期。在去年同期，該公司每股盈利 0.72 美元。分析師平均預計，氙製藥今年將每股虧損 3.16 美元。</p>
<h2>機構投資者對氙製藥的看法</h2>
<p>一些對沖基金最近買入和賣出了該公司的股票。Parallel Advisors LLC 在第四季度將其在氙製藥的持倉增加了 51.2%。Parallel Advisors LLC 現在擁有該生物製藥公司的 1,125 股股票，價值 52,000 美元，較上一季度增加了 381 股。PNC 金融服務集團在第四季度購入了氙製藥的新頭寸，價值約 91,000 美元。17 Capital Partners LLC 在第一季度購入了氙製藥的新頭寸，價值約 122,000 美元。Quarry LP 在第二季度將其在氙製藥的持倉增加了 207.7%。Quarry LP 現在擁有該生物製藥公司的 4,000 股股票，價值 156,000 美元，較上一季度增加了 2,700 股。最後，EntryPoint Capital LLC 在第一季度購入了氙製藥的新股份，價值 195,000 美元。對沖基金和其他機構投資者擁有該公司 95.45% 的股份。</p>
<h2>氙製藥公司簡介（獲取免費報告）</h2>
<p>氙製藥公司是一家總部位於加拿大的臨牀階段生物製藥公司，致力於開發治療神經系統疾病患者的治療藥物。其臨牀開發管線包括 XEN496，一種 Kv7 鉀通道開啓劑，目前處於用於治療 KCNQ2 發育性和癲癇性腦病的 III 期臨牀試驗階段；以及 XEN1101，一種 Kv7 鉀通道開啓劑，目前處於用於治療癲癇和其他神經系統疾病的 II 期臨牀試驗階段。</p>
<h2>推薦故事</h2>
<ul>
<li>我們喜歡的五支股票比氙製藥更好</li>
<li>什麼是支撐位？</li>
<li>投資穩定性：動盪市場的前三大藍籌股</li>
<li>什麼是道·瓊斯狗策略？概述和示例</li>
<li>Joby Aviation 股票：您的下一個高增長機會</li>
<li>交易停牌解釋</li>
<li>不要輕視 CrowdStrike：來自 Q2 財報的關鍵見解</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WEVORQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WEVORQ"/></p>
<p><em>此即時新聞警報由 Narrative Science 技術和 MarketBeat 的財務數據生成，以向讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<p>→ 免費每日利潤現場開放日（來自紀念碑交易聯盟）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NDM5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NDM5"/></p>
<h2>您現在應該投資 1000 美元在氙製藥嗎？</h2>
<p>在考慮氙製藥之前，您會想聽到這個。</p>
<p>MarketBeat 追蹤華爾街評級最高且表現最佳的研究分析師以及他們每日向客户推薦的股票。MarketBeat 已確定了五支頂級分析師悄悄告訴客户現在購買的股票...而氙製藥不在名單上。</p>
<p>儘管氙製藥目前在分析師中有&#34;買入&#34;評級，但頂級分析師認為這五支股票更值得購買。</p>
<p>查看這五支股票</p>

Xenon制藥

<p>加拿大皇家銀行重申對 Xenon Pharmaceuticals（NASDAQ：XENE）的 “表現優異” 評級，並設定了一個價格目標，顯示潛在上漲幅度為 33.24%。其他分析師也發表了看法，評級從 “買入” 到 “超配” 不等。目前，Xenon 獲得了 “中等買入” 的共識評級，平均目標價為 9.78 美元。Xenon 的股價在報告當天上漲了 2.3%</p>

<p>Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report)'s stock had its &#34;outperform&#34; rating reissued by equities researchers at Royal Bank of Canada in a research report issued on Tuesday, Benzinga reports. They presently have a $55.00 price target on the biopharmaceutical company's stock. Royal Bank of Canada's price target points to a potential upside of 33.24% from the stock's current price.</p>
<div class="lb-trans"><p>週二，彭博社報道，皇家銀行的股票研究員重申了對氙製藥（Xenon Pharmaceuticals，NASDAQ：XENE）的&#34;表現優異&#34;評級。他們目前將這家生物製藥公司的股票定價目標定為 55.00 美元。皇家銀行的股價目標顯示，相較於當前股價，潛在上漲空間為 33.24%。</p>
</div><p>Get <strong>Xenon Pharmaceuticals</strong> alerts:</p>
<ul>
<li>Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals</li>
</ul>
<div class="lb-trans"><p>獲取 <strong>氙製藥</strong> 的警報：</p>
<ul>
<li>百時美施貴寶的大舉購買：在兩筆生物科技交易中斥資 181 億美元</li>
</ul>
</div><p>A number of other analysts have also recently issued reports on XENE. Cantor Fitzgerald reissued an &#34;overweight&#34; rating and issued a $65.00 price objective on shares of Xenon Pharmaceuticals in a research note on Friday, August 9th. Wedbush lowered their price objective on Xenon Pharmaceuticals from $50.00 to $49.00 and set an &#34;outperform&#34; rating on the stock in a research report on Friday, August 9th. Needham &amp; Company LLC cut their target price on Xenon Pharmaceuticals from $62.00 to $60.00 and set a &#34;buy&#34; rating for the company in a research report on Monday, August 12th. Finally, Citigroup lowered their price target on Xenon Pharmaceuticals from $62.00 to $60.00 and set a &#34;buy&#34; rating on the stock in a report on Friday, May 10th. One investment analyst has rated the stock with a sell rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat.com, Xenon Pharmaceuticals presently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $58.78.</p>
<div class="lb-trans"><p>其他一些分析師最近也發佈了關於 XENE 的報告。卡恩特菲茨傑拉德（Cantor Fitzgerald）重申了&#34;超重&#34;評級，並在 8 月 9 日星期五的研究報告中給出了 65.00 美元的股價目標。Wedbush 在 8 月 9 日星期五的研究報告中將氙製藥的股價目標從 50.00 美元降至 49.00 美元，並給予&#34;表現優異&#34;評級。Needham &amp; Company LLC 在 8 月 12 日星期一的研究報告中將氙製藥的目標股價從 62.00 美元降至 60.00 美元，並給予&#34;買入&#34;評級。最後，花旗集團在 5 月 10 日星期五的報告中將氙製藥的股價目標從 62.00 美元降至 60.00 美元，並給予&#34;買入&#34;評級。一位投資分析師對該股票給予賣出評級，而九位分析師則給予該公司股票買入評級。根據 MarketBeat.com 的數據，氙製藥目前的共識評級為&#34;中度買入&#34;，平均目標股價為 58.78 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on XENE</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 XENE 的最新股票分析</strong></p>
</div><h2>Xenon Pharmaceuticals Trading Up 2.3 %</h2>
<div class="lb-trans"><h2>氙製藥股價上漲 2.3%</h2>
</div><p>Xenon Pharmaceuticals stock traded up $0.94 during trading on Tuesday, reaching $41.28. The company had a trading volume of 14,893 shares, compared to its average volume of 395,175. The firm has a market capitalization of $3.13 billion, a price-to-earnings ratio of -15.10 and a beta of 1.25. The firm's 50-day simple moving average is $40.29 and its 200 day simple moving average is $41.46. Xenon Pharmaceuticals has a 52 week low of $27.99 and a 52 week high of $50.99.</p>
<div class="lb-trans"><p>週二交易日，氙製藥股價上漲 0.94 美元，達到 41.28 美元。該公司的交易量為 14,893 股，相比平均交易量 395,175 股。該公司的市值為 31.3 億美元，市盈率為-15.10，貝塔係數為 1.25。該公司的 50 天簡單移動平均線為 40.29 美元，200 天簡單移動平均線為 41.46 美元。氙製藥的 52 周最低價為 27.99 美元，52 周最高價為 50.99 美元。</p>
</div><p>Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.05). During the same period in the previous year, the company earned ($0.72) earnings per share. On average, analysts predict that Xenon Pharmaceuticals will post -3.16 earnings per share for the current year.</p>
<div class="lb-trans"><p>氙製藥（Xenon Pharmaceuticals，NASDAQ：XENE）於 8 月 8 日星期四公佈了季度財報。這家生物製藥公司在該季度報告中每股虧損 0.75 美元，低於每股虧損 0.70 美元的共識預期。在去年同期，該公司每股盈利 0.72 美元。分析師平均預計，氙製藥今年將每股虧損 3.16 美元。</p>
</div><h2>Institutional Investors Weigh In On Xenon Pharmaceuticals</h2>
<div class="lb-trans"><h2>機構投資者對氙製藥的看法</h2>
</div><p>A number of hedge funds have recently bought and sold shares of the business. Parallel Advisors LLC raised its position in shares of Xenon Pharmaceuticals by 51.2% during the 4th quarter. Parallel Advisors LLC now owns 1,125 shares of the biopharmaceutical company's stock valued at $52,000 after buying an additional 381 shares in the last quarter. PNC Financial Services Group Inc. purchased a new position in shares of Xenon Pharmaceuticals in the 4th quarter worth approximately $91,000. 17 Capital Partners LLC bought a new position in shares of Xenon Pharmaceuticals during the 1st quarter valued at approximately $122,000. Quarry LP increased its position in shares of Xenon Pharmaceuticals by 207.7% during the 2nd quarter. Quarry LP now owns 4,000 shares of the biopharmaceutical company's stock valued at $156,000 after purchasing an additional 2,700 shares during the last quarter. Finally, EntryPoint Capital LLC purchased a new stake in Xenon Pharmaceuticals during the 1st quarter valued at $195,000. Hedge funds and other institutional investors own 95.45% of the company's stock.</p>
<div class="lb-trans"><p>一些對沖基金最近買入和賣出了該公司的股票。Parallel Advisors LLC 在第四季度將其在氙製藥的持倉增加了 51.2%。Parallel Advisors LLC 現在擁有該生物製藥公司的 1,125 股股票，價值 52,000 美元，較上一季度增加了 381 股。PNC 金融服務集團在第四季度購入了氙製藥的新頭寸，價值約 91,000 美元。17 Capital Partners LLC 在第一季度購入了氙製藥的新頭寸，價值約 122,000 美元。Quarry LP 在第二季度將其在氙製藥的持倉增加了 207.7%。Quarry LP 現在擁有該生物製藥公司的 4,000 股股票，價值 156,000 美元，較上一季度增加了 2,700 股。最後，EntryPoint Capital LLC 在第一季度購入了氙製藥的新股份，價值 195,000 美元。對沖基金和其他機構投資者擁有該公司 95.45% 的股份。</p>
</div><h2>Xenon Pharmaceuticals Company Profile (Get Free Report)</h2>
<div class="lb-trans"><h2>氙製藥公司簡介（獲取免費報告）</h2>
</div><p>Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders.</p>
<div class="lb-trans"><p>氙製藥公司是一家總部位於加拿大的臨牀階段生物製藥公司，致力於開發治療神經系統疾病患者的治療藥物。其臨牀開發管線包括 XEN496，一種 Kv7 鉀通道開啓劑，目前處於用於治療 KCNQ2 發育性和癲癇性腦病的 III 期臨牀試驗階段；以及 XEN1101，一種 Kv7 鉀通道開啓劑，目前處於用於治療癲癇和其他神經系統疾病的 II 期臨牀試驗階段。</p>
</div><h2>Recommended Stories</h2>
<ul>
<li>Five stocks we like better than Xenon Pharmaceuticals</li>
<li>What is a support level?</li>
<li>Invest in Stability: Top 3 Blue-Chip Stocks for Turbulent Markets</li>
<li>What is the Dogs of the Dow Strategy? Overview and Examples</li>
<li>Joby Aviation Stock: Your Next High-Growth Opportunity</li>
<li>Trading Halts Explained</li>
<li>Don’t Count Out CrowdStrike Yet: Key Insights from Q2 Earnings</li>
</ul>
<div class="lb-trans"><h2>推薦故事</h2>
<ul>
<li>我們喜歡的五支股票比氙製藥更好</li>
<li>什麼是支撐位？</li>
<li>投資穩定性：動盪市場的前三大藍籌股</li>
<li>什麼是道·瓊斯狗策略？概述和示例</li>
<li>Joby Aviation 股票：您的下一個高增長機會</li>
<li>交易停牌解釋</li>
<li>不要輕視 CrowdStrike：來自 Q2 財報的關鍵見解</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WEVORQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=XENE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由 Narrative Science 技術和 MarketBeat 的財務數據生成，以向讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><p>→ FREE Daily Profits Live Open House (From Monument Traders Alliance)(Ad)</p>
<div class="lb-trans"><p>→ 免費每日利潤現場開放日（來自紀念碑交易聯盟）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NDM5" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9439&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Xenon Pharmaceuticals right now?</h2>
<div class="lb-trans"><h2>您現在應該投資 1000 美元在氙製藥嗎？</h2>
</div><p>Before you consider Xenon Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮氙製藥之前，您會想聽到這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追蹤華爾街評級最高且表現最佳的研究分析師以及他們每日向客户推薦的股票。MarketBeat 已確定了五支頂級分析師悄悄告訴客户現在購買的股票...而氙製藥不在名單上。</p>
</div><p>While Xenon Pharmaceuticals currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管氙製藥目前在分析師中有&#34;買入&#34;評級，但頂級分析師認為這五支股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五支股票</p>
</div>

加拿大皇家銀行重申了對 Xenon 製藥（納斯達克：XENE）的評級